Inflammatory Bowel Disease

Discussing the latest advances in Crohn’s disease and ulcerative colitis

Items Tagged ‘Vedolizumab’

May 3, 2016

Vedolizumab Safe for Inflammatory Bowel Disease

By Kanaaz Pereira kanaazpe

Vedolizumab (proposed trade name Entyvio), was developed as a treatment for patients with moderate to severe ulcerative colitis (UC) or Crohn’s disease (CD), who have failed at least one conventional therapy, including tumor necrosis factor (TNF) antagonists. Dr. Edward Loftus, M.D., reviews a recent study published in the journal Gut, in which researchers reported on […]

View full entry

Tags: Crohn's disease, Edward Loftus, Entyvio, GUT, IBD, monoclonal antibody, ulcerative colitis, Vedolizumab


February 13, 2015

Latest Gastroenterology Innovations

By Margaret Shepard, Communications Specialist Margaret_Marie

The past few years have been important ones for advances in gastroenterology medicine. Among the many new developments are minimally invasive surgical techniques, simpler diagnostic tests and medications with fewer side effects and higher success rates. Read about some of the exciting GI innovations of the past year. Content originally posted on mayoclinic.org.

View full entry

Tags: Gastroenterology, GI, IBD, innovations, Vedolizumab


December 18, 2014

Vedolizumab Is Better for Ulcerative Colitis Than Crohn’s Disease

By Margaret Shepard, Communications Specialist Margaret_Marie

In December 2013, two Food and Drug Administration (FDA) advisory committees voted in favor of recommending vedolizumab for treatment of both types of inflammatory bowel disease. A theoretical concern about vedolizumab is the risk of progressive multifocal leukoencephalopathy (PML), a potentially fatal brain infection associated with vedolizumab’s parent molecule, natalizumab (Tysabri), which is approved for […]

View full entry

Tags: clinical trials, Crohn's disease, Edward Loftus, IBD, ulcerative colitis, Vedolizumab


October 9, 2014

Crohn’s Disease and Remission with Vedolizumab

By Margaret Shepard, Communications Specialist Margaret_Marie

Edward Loftus Jr., M. D., discusses a recent article published in Gastroenterology looking at how well vedolizumab works with Crohn’s disease patients who have already been on an anti-TNF agent.   The study specifically examined the question of how well vedolizumab in patients with Crohn’s disease who have already been on a different type of […]

View full entry

Tags: Crohn's disease, Edward Loftus, Gastroenterology, Vedolizumab


February 11, 2014

Vedolizumab Being Reviewed by the FDA

By Margaret Shepard, Communications Specialist Margaret_Marie

Ed Loftus, M.D., discusses recent developments on a drug, vedolizumab, that is currently being reviewed by the Food and Drug Administration for inflammatory bowel disease. Vedolizumab is thought to be more gut specific and potentially have fewer adverse side effects. http://www.youtube.com/watch?v=A2km-E53sLI In December, an advisory committee convened by the FDA met to review all the data […]

View full entry

Tags: Edward Loftus, FDA, Vedolizumab


Contact Us · Privacy Policy